JP2017515858A - Ａｄｈｄの治療のためのダソトラリンに関する方法および組成物 - Google Patents

Ａｄｈｄの治療のためのダソトラリンに関する方法および組成物 Download PDF

Info

Publication number
JP2017515858A
JP2017515858A JP2016567685A JP2016567685A JP2017515858A JP 2017515858 A JP2017515858 A JP 2017515858A JP 2016567685 A JP2016567685 A JP 2016567685A JP 2016567685 A JP2016567685 A JP 2016567685A JP 2017515858 A JP2017515858 A JP 2017515858A
Authority
JP
Japan
Prior art keywords
dasotraline
treatment
adhd
dosage form
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016567685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515858A5 (enExample
Inventor
アントニー・ディ・ローベル
ケネス・エス・コブラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of JP2017515858A publication Critical patent/JP2017515858A/ja
Publication of JP2017515858A5 publication Critical patent/JP2017515858A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016567685A 2014-05-13 2015-05-12 Ａｄｈｄの治療のためのダソトラリンに関する方法および組成物 Pending JP2017515858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992588P 2014-05-13 2014-05-13
US61/992,588 2014-05-13
PCT/US2015/030342 WO2015175514A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd

Publications (2)

Publication Number Publication Date
JP2017515858A true JP2017515858A (ja) 2017-06-15
JP2017515858A5 JP2017515858A5 (enExample) 2018-06-21

Family

ID=54480544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567685A Pending JP2017515858A (ja) 2014-05-13 2015-05-12 Ａｄｈｄの治療のためのダソトラリンに関する方法および組成物

Country Status (10)

Country Link
US (1) US20170266133A1 (enExample)
EP (1) EP3142999A4 (enExample)
JP (1) JP2017515858A (enExample)
KR (1) KR20170003677A (enExample)
CN (1) CN106660936A (enExample)
AU (1) AU2015259337A1 (enExample)
CA (1) CA2948829A1 (enExample)
IL (1) IL248846A0 (enExample)
MX (1) MX2016014780A (enExample)
WO (1) WO2015175514A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019143920A1 (en) * 2018-01-19 2019-07-25 Sunovion Pharmaceuticals Inc. Oral dosage forms
US20210386689A1 (en) * 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512921A (ja) * 2009-12-04 2013-04-18 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
PT1542961E (pt) * 2002-09-16 2013-11-05 Sunovion Pharmaceuticals Inc Trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1- naftalenamina para uso no tratamento de perturbações do sistema nervoso central
EP2707000A4 (en) * 2011-05-13 2014-11-26 Dainippon Sumitomo Pharma Co TREATMENT AND CONTROL OF CNS DISORDERS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512921A (ja) * 2009-12-04 2013-04-18 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用

Also Published As

Publication number Publication date
WO2015175514A1 (en) 2015-11-19
CN106660936A (zh) 2017-05-10
AU2015259337A1 (en) 2016-12-08
IL248846A0 (en) 2017-01-31
EP3142999A4 (en) 2017-12-27
MX2016014780A (es) 2017-07-25
EP3142999A1 (en) 2017-03-22
CA2948829A1 (en) 2015-11-19
US20170266133A1 (en) 2017-09-21
KR20170003677A (ko) 2017-01-09

Similar Documents

Publication Publication Date Title
Biederman et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD
Donohue et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol
JP2021098743A (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
AU2018342072B2 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
US20170151214A1 (en) Method for the treatment of dravet syndrome
KR102649644B1 (ko) 편두통 예방을 위한 라스미디탄의 만성 야간 투여
WO2016044150A1 (en) VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
Lasser et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial
Paton Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome
Al‐Qassab et al. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study
JP2017515858A (ja) Ａｄｈｄの治療のためのダソトラリンに関する方法および組成物
Glazer et al. The treatment of tardive dyskinesia with baclofen
US10076503B2 (en) Dosage of dasotraline and method for treatment of ADHD
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
US20240342160A1 (en) Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
Zheng et al. Randomized, double-blind, placebo-controlled trial on the efficacy, safety and tolerability of modified-release methylphenidate (MPH-MR) in Chinese children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
Poole Atomoxetine: long-term treatment benefits in ADHD
KR20240013810A (ko) 간 손상을 갖는 개체에의 화합물의 투여
Lipavský P. 1.075 Citalopram in depressed cardiac patients
Tiseo et al. P. 4.023 The pharmacokinetics and pharmacodynamics of (R)-and (S)-Warfarin are unaffected by co-administration of donepezil
Tiseo et al. P. 4.024 Co-administration of donepezil and digoxin produces no pharmacokinetic or pharmacodynamic interactions
MARLBOROUGH Diagnostic and Statistical Manual of Mental Disorders, Text Revision. In this study, Vyvanse demonstrated a reduction (approximately 52%)
Dushanova P. 4.026 Ticlid in the treatment of atherosclerotic encephalopathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191015